DXCM
FY2026 Q1 · Calendar Q2 2026
DexCom, Inc.
Dexcom reported a strong Q1 FY2026 with revenue of $1.19B (up 15% YoY, 12% organic) and EPS of $0.56, both beating consensus. The G7 15-day CGM launch is driving record new-patient starts, conversions, and gross margin expansion. Management reaffirmed full-year revenue guidance of $5.16-$5.20B and raised operating and EBITDA margin targets, while disclosing a 50-100 bps inflation headwind from oil and resin costs. Key catalysts ahead include potential CMS coverage for type-2 non-insulin patients, the international Stello launch, and an Investor Day. The stock gained 2.75% on the report and has since drifted +22%, with the analyst consensus target at $84.18 versus the current price of $73.81.
EPS surprise+20.3%
Market move+3.0%
